TORONTO, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) — Titan Medical (OTC:) Inc. (Titan) (TSX: ™D; OTC: ™DIF) pronounces that Conavi Medical Inc. (Conavi) will likely be becoming a member of the beforehand introduced Titan Q&A session to be held on Thursday, September 19, 2024 at 5:00 pm ET in reference to the proposed enterprise mixture between Titan and Conavi to be thought-about on the annual common assembly of Titan on September 30, 2024. After the Conavi presentation, Titan will present ready remarks adopted by a Q&A session. Paul Cataford, Interim President and CEO and Chien Huang, Chief Monetary Officer will attend the session on behalf of Titan.
Shareholders are invited to submit questions upfront of the Q&A session to traders@titanmedicalinc.com. Questions will likely be accepted till September 17, 2024 at 1:00 pm ET. A hyperlink to the reside audio webcast will likely be made out there on the Buyers Relations part of the Firm’s web site, www.titanmedicalinc.com.
Tom Looby, Chief Govt Officer of Conavi Medical Inc. (Conavi) will current data on Conavi, together with Conavi’s patented Novasight Hybrid™ System for minimally invasive cardiovascular procedures.
About Titan Medical
Titan Medical Inc. (TSX: ™D; OTC: ™DIF), a medical expertise firm integrated below the Enterprise Firms Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio associated to the enhancement of robotic assisted surgical procedure (RAS), together with by way of a single entry level, and is presently targeted on evaluating new alternatives to additional develop and license its mental property.
About Conavi Medical
Conavi Medical Inc. is a privately-owned firm targeted on designing, manufacturing, and advertising imaging applied sciences to information frequent minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the primary system to mix each IVUS and OCT to allow simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(ok) clearance from the U.S. Meals and Drug Administration; and regulatory approval for medical use from Well being Canada, China’s Nationwide Medical Merchandise Administration, and Japan’s Ministry of Well being, Labor and Welfare. For extra data, go to http://www.conavi.com/.
Cautionary Assertion Concerning Ahead-Wanting Info
This information launch accommodates forward-looking statements inside the that means of relevant Canadian and U.S. securities legal guidelines, which mirror the present expectations of administration of Titan’s future progress, outcomes of operations, efficiency and enterprise prospects and alternatives. Ahead-looking statements are continuously, however not all the time, recognized by phrases akin to could, would, may, will, anticipate, imagine, plan, anticipate, intend, estimate, potential for and related expressions, though these phrases is probably not current in all forward-looking statements. Ahead-looking statements that seem on this launch could embody, with out limitation, references to: the continued work of Titan and Conavi in the direction of the completion of the Transaction and the anticipated date of the Assembly.
These forward-looking statements mirror administration’s present beliefs with respect to future occasions, and are based mostly on data presently out there to administration that, whereas thought-about cheap by administration as of the date on which the statements are made, are inherently topic to important enterprise, financial and aggressive uncertainties and contingencies which may end in actions, occasions, situations, outcomes, efficiency or achievements to be materially totally different from these projected within the forward-looking statements. Ahead-looking statements contain important dangers, uncertainties and assumptions and plenty of elements may trigger Titan’s precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements which may be expressed or implied by such forward-looking statements. Such elements and assumptions embody, however will not be restricted to, Titan’s means to retain key personnel; its means to execute on its enterprise plans and techniques; its means to proceed to license some or all its mental property to 3rd events and obtain any materials consideration; the receipt of required approvals from the TSXV and Titan’s shareholders in reference to the Transaction or change of itemizing or as to the success of Conavi’s Concurrent Financing (or the phrases upon which such financing could also be out there if in any respect)and different elements listed within the Threat Elements part of Titan’s Annual Info Type for the fiscal 12 months ended December 31, 2023 (which can be considered at www.sedarplus.com). Ought to a number of of those dangers or uncertainties materialize, or ought to assumptions underlying the forward-looking statements show incorrect, precise outcomes, efficiency, or achievements could differ materially from these expressed or implied by the forward-looking statements contained on this information launch. These elements ought to be thought-about rigorously, and potential traders mustn’t place undue reliance on the forward-looking statements.
Though the forward-looking statements contained within the information launch are based mostly upon what administration presently believes to be cheap assumptions and Titan has tried to determine necessary elements that would trigger precise actions, occasions, situations, outcomes, efficiency or achievements to vary materially from these described in forward-looking statements, Titan can’t guarantee potential traders that precise outcomes, efficiency or achievements will likely be in line with these forward-looking statements. Besides as required by regulation, Titan expressly disclaims any intention or obligation to replace or revise any forward-looking statements whether or not because of new data, future occasions or in any other case. Accordingly, traders mustn’t place undue reliance on forward-looking statements. All of the forward-looking statements are expressly certified by the foregoing cautionary statements.
Contacts
Titan Medical Inc.
Chien Huang
Chief Monetary Officer
traders@titanmedicalinc.com
###
Supply: Titan Medical Inc.